NOTA-AE105
Based on 1 Customer Validation
NOTA-AE105 is a uPAR-targeting PET imaging ligand. NOTA-AE105 can be radiolabeled with 64Cu and 68Ga. NOTA-AE105 binds to the urokinase-type plasminogen activator receptor, thereby enabling PET imaging of uPAR expression in tumor tissues. NOTA-AE105 can be used for research on head and neck squamous cell carcinoma, breast cancer, prostate cancer, bladder cancer, and glioblastoma.
For research use only. We do not sell to patients.
- Purity : 98.99%
- CAS No.: 1820563-84-5
- Formula: C72H102N16O20
- Molecular Weight:1511.68
-
Storage:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
NOTA-AE105 can be radiolabeled with 64Cu and 68Ga to yield high specific activity and high radiochemical purity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1820563-84-5
-
Appearance Solid
-
Molecular Weight 1511.68
-
Formula C72H102N16O20
-
Color White to off-white
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Solvent & Solubility
In Vitro:
DMSO : 83.33 mg/mL (55.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
-
Data Sheet (291 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Risør LM, et al. Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with F-FDG PET/CT: A Single-Center Prospective Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2022 Aug;63(8):1169-1176. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.6615 mL | 3.3076 mL | 6.6152 mL | 16.5379 mL |
| 5 mM | 0.1323 mL | 0.6615 mL | 1.3230 mL | 3.3076 mL | |
| 10 mM | 0.0662 mL | 0.3308 mL | 0.6615 mL | 1.6538 mL | |
| 15 mM | 0.0441 mL | 0.2205 mL | 0.4410 mL | 1.1025 mL | |
| 20 mM | 0.0331 mL | 0.1654 mL | 0.3308 mL | 0.8269 mL | |
| 25 mM | 0.0265 mL | 0.1323 mL | 0.2646 mL | 0.6615 mL | |
| 30 mM | 0.0221 mL | 0.1103 mL | 0.2205 mL | 0.5513 mL | |
| 40 mM | 0.0165 mL | 0.0827 mL | 0.1654 mL | 0.4134 mL | |
| 50 mM | 0.0132 mL | 0.0662 mL | 0.1323 mL | 0.3308 mL |
NOTA-AE105 Related Classifications
HY-P5018 Related Classifications
Powered by Bioz
Keywords
- NOTA-AE105
- 1820563-84-5
- Biochemical Assay Reagents
- urinary bladder cancer
- uPAR-targeting PET imaging ligand
- renal excretion
- glioblastoma
- head and neck squamous cell carcinoma
- orthotopic glioblastoma model
- breast cancer
- urokinase-type plasminogen activator receptor
- prostate cancer
- uPAR expression
- Inhibitor
- inhibitor
- inhibit